LONDON, Nov 22 (Reuters) - European regulators said onFriday they had recommended approval of a new drug for HIV fromGlaxoSmithKline and a novel hepatitis C treatment fromGilead Sciences.
The European Medicine Agency (EMA) also gave a green lightto an Otsuka tuberculosis drug, following a review ofan earlier rejection.
Recommendations for marketing approval by the EMA'sCommittee for Medicinal Products for Human Use (CHMP) arenormally endorsed by the European Commission within a couple ofmonths.